0.0085  -0.107 (-92.64%)		04-11 15:58
Open: 0.015 High: 0.02 Volume: 1,943,400		Pre. Close: 0.1155 Low: 0.0075 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Otonomy, Inc., a biopharmaceutical firm established in 2008 and headquartered in San Diego, California, concentrates on pioneering treatments for neurotological disorders throughout the United States. Its robust pipeline includes several programs: OTO-313, a sustained-release formulation of the N-methyl-D-aspartate receptor antagonist gacyclidine, currently in Phase II clinical trials for addressing tinnitus; and OTO-413, a sustained-exposure brain-derived neurotrophic factor, which is undergoing Phase IIa studies to mend cochlear synaptopathy and alleviate speech-in-noise hearing difficulties. The company is also advancing OTO-510, an otoprotectant designed to prevent hearing loss induced by cisplatin, along with OTO-825, a gene therapy aimed at congenital hearing loss. Additionally, OTO-6XX is being developed to stimulate hair cell repair and regeneration for severe hearing impairment. Otonomy holds licensing agreements with the University of California and DURECT Corporation, and has a strategic alliance with Applied Genetic Technologies Corporation focused on gene therapy solutions for congenital hearing loss.

Mon, 21 Nov 2022
Orin Hirschman Discloses Large Position in CGTX / Cognition Therapeutics - 24/7 Wall St.

Fri, 12 Nov 2021
Otonomy Partners with Kyorin Pharmaceutical on Hearing Loss Compound - The Hearing Review

Fri, 12 Nov 2021
Otonomy Initiates Clinical Trial for Tinnitus Drug - The Hearing Review

Thu, 11 Nov 2021
FDA Approves OTIPRIO for the Treatment of Children Undergoing Tympanostomy Tube Placement Surgery - The Hearing Review

Thu, 03 Jun 2021
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients - PR Newswire

Thu, 07 Feb 2019
Biotech Stocks Facing FDA Decision In March - RTTNews

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date